iifl-logo

Aurobindo Pharma Ltd Share Price

1,148.5
(1.27%)
Apr 2, 2025|11:19:59 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,133
  • Day's High1,150.7
  • 52 Wk High1,592
  • Prev. Close1,134.15
  • Day's Low1,117.4
  • 52 Wk Low 1,031.05
  • Turnover (lac)3,892.18
  • P/E34.68
  • Face Value1
  • Book Value359.45
  • EPS32.72
  • Mkt. Cap (Cr.)67,295.05
  • Div. Yield0.4
View All Historical Data

Aurobindo Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,133

Prev. Close

1,134.15

Turnover(Lac.)

3,892.18

Day's High

1,150.7

Day's Low

1,117.4

52 Week's High

1,592

52 Week's Low

1,031.05

Book Value

359.45

Face Value

1

Mkt Cap (₹ Cr.)

67,295.05

P/E

34.68

EPS

32.72

Divi. Yield

0.4

Aurobindo Pharma Ltd Corporate Action

10 Feb 2024

12:00 AM

Dividend

Dividend Amount: 1.5

Record Date: 20 Feb, 2024

arrow

30 Jul 2024

12:00 AM

BookCloser

arrow

30 Jul 2024

12:00 AM

AGM

Announcement Date: 30 Jul, 2024

arrow

17 Jan 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Aurobindo Pharma Ltd NEWS AND UPDATE

Aurobindo Pharma’s Eugia gets 5 observations from USFDA
19 Feb 2025|01:39 PM

As per the company’s filing with the bourses, the inspection was concluded with five procedural observations.

Read More
Aurobindo Pharma Q3 Profit Falls 9.7% YoY, Revenue Up 8.5%
6 Feb 2025|11:06 PM

Revenue increased by 8.5% YoY to ₹7,978.5 crore.

Read More
Aurobindo Pharma’s Telangana API Facility Gets USFDA VAI Classification
28 Jan 2025|01:22 PM

The USFDA inspected the Unit 2 API manufacturing facility of Apitoria Pharma during September 23 to September 27, 2024

Read More
Aurobindo Pharma Gains UK Approval for Cancer Drug Bevqolva
23 Dec 2024|11:11 PM

This is a medicine used to treat specific kinds of cancer. It can be administered only via an infusion.

Read More
Top Stocks for today - 23rd December 2024
23 Dec 2024|07:33 AM

Here are some of the stocks that may see significant price movement today: Vedanta, NHPC, Reliance Industries, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Aurobindo Pharma Ltd SHAREHOLDING SNAPSHOT

02 Apr, 2025|11:46 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 3.07%

Foreign: 3.07%

Indian: 48.74%

Non-Promoter- 41.50%

Institutions: 41.49%

Non-Institutions: 6.68%

Custodian: 0.00%

Share Price

Aurobindo Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

58.59

58.59

58.59

58.59

Preference Capital

0

0

0

0

Reserves

19,664.23

17,975.44

17,058.75

15,866.02

Net Worth

19,722.82

18,034.03

17,117.34

15,924.61

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

11,287.14

15,823.68

13,266.48

10,269.9

yoy growth (%)

-28.66

19.27

29.17

6.89

Raw materials

-5,846.25

-7,244.82

-6,523.53

-4,562.81

As % of sales

51.79

45.78

49.17

44.42

Employee costs

-1,600.04

-1,735.42

-1,561.47

-1,131.64

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

1,712.19

4,193.01

2,377.7

2,342.94

Depreciation

-415.26

-488

-470.48

-354.83

Tax paid

-182.77

-1,080.1

-504.96

-530.17

Working capital

-1,929.49

771.58

1,700.35

1,554.63

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-28.66

19.27

29.17

6.89

Op profit growth

-64.23

53.39

0.58

12.47

EBIT growth

-59.04

61.21

9.29

7.73

Net profit growth

-53.26

66.22

3.3

6.21

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

28,704.5

24,617.13

23,366.55

24,557.95

22,737.95

Excise Duty

0

0

0

0

0

Net Sales

28,704.5

24,617.13

23,366.55

24,557.95

22,737.95

Other Operating Income

297.37

238.25

88.94

216.68

360.55

Other Income

557.38

290.59

320.35

3,195.42

86.2

Aurobindo Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,698.35

129.244,07,155.151,181.050.85,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,549.7

71.051,47,295.245940.542,297513.62

Cipla Ltd

CIPLA

1,444.25

25.071,16,664.331,438.150.94,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,183.9

59.031,07,673.274850.882,330222.38

Mankind Pharma Ltd

MANKIND

2,458.1

52.421,01,358.17416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Aurobindo Pharma Ltd

Management

Register Office

Registrar Office

Vice Chairman & M.D.

Kambam Nityananda Reddy

Whole-time Director

M Madan Mohan Reddy

Non Executive Director

P V Ramprasad Reddy

Independent Director

Savita Mahajan

Independent Director

Girish Paman Vanvari

Non Executive Director

P Sarath Chandra Reddy

Independent Director

Santanu Mukherjee

Independent Director

Deepali Pant Joshi

Chairman & Independent Directo

M R Kumar

Non Executive Director

Satakarni Makkapati

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Aurobindo Pharma Limited (APL), one of the worlds top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The companys robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindos products. APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SS
Read More

Company FAQs

What is the Aurobindo Pharma Ltd share price today?

The Aurobindo Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1148.5 today.

What is the Market Cap of Aurobindo Pharma Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aurobindo Pharma Ltd is ₹67295.05 Cr. as of 02 Apr ‘25

What is the PE and PB ratio of Aurobindo Pharma Ltd?

The PE and PB ratios of Aurobindo Pharma Ltd is 34.68 and 3.38 as of 02 Apr ‘25

What is the 52 Week High and Low of Aurobindo Pharma Ltd?

The 52-week high/low is the highest and lowest price at which a Aurobindo Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Aurobindo Pharma Ltd is ₹1031.05 and ₹1592 as of 02 Apr ‘25

What is the CAGR of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd's CAGR for 5 Years at 23.65%, 3 Years at 18.46%, 1 Year at 1.87%, 6 Month at -21.15%, 3 Month at -16.19% and 1 Month at 6.74%.

What is the shareholding pattern of Aurobindo Pharma Ltd?

The shareholding pattern of Aurobindo Pharma Ltd is as follows:
Promoters - 51.82 %
Institutions - 41.50 %
Public - 6.69 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.